Reduced erlotinib sensitivity of EGFR mutant non-small cell lung cancer following cisplatin exposure: A cell culture model of second-line erlotinib treatment

समान संसाधन

• Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib
  द्वारा: Nishino, Mizuki, और अन्य
  प्रकाशित: (2016)
• Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer
  द्वारा: Lo, Peter C., और अन्य
  प्रकाशित: (2015)
• A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small Cell Lung Cancer
  द्वारा: Goldberg, Sarah B., और अन्य
  प्रकाशित: (2012)
• The Anticipated Next Season of EGFR Inhibitors
  द्वारा: Sequist, Lecia V.
  प्रकाशित: (2015)
• Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers
  द्वारा: Khandekar, Melin J., और अन्य
  प्रकाशित: (2018)